Orchestra BioMed Holdings (OBIO) Net Cash Flow (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Net Cash Flow for 6 consecutive years, with -$6.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 61.59% year-over-year to -$6.3 million; the TTM figure through Mar 2026 stood at $10.0 million (up 301.35% YoY), while the FY2025 annual figure was $12.4 million, up 249.78% from the prior year.
• Net Cash Flow improved to -$6.3 million in Q1 2026 per OBIO's latest filing, from -$7.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $77.6 million in Q2 2022 and bottomed at -$77.2 million in Q4 2022.
• Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of -$1.1 million in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 198454.75% in 2022 and fell as far as 267668.34% in 2022.
• Orchestra BioMed Holdings' Net Cash Flow stood at -$77.2 million in 2022, then surged by 114.87% to $11.5 million in 2023, then sank by 129.13% to -$3.3 million in 2024, then plunged by 118.96% to -$7.3 million in 2025, then increased by 13.64% to -$6.3 million in 2026.
• Business Quant data shows OBIO's Net Cash Flow at -$6.3 million in Q1 2026, -$7.3 million in Q4 2025, and $23.3 million in Q3 2025.